National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Blood Stem Cell Transplants
< Back to Main
In English     En español
    Posted: 09/01/2006    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Slide 19  :  Preparing Patients for Myeloablative Allogeneic Transplants <  >  

Before receiving allogeneic transplants--the most common type--patients with blood cancers must undergo a conditioning regimen of high-dose chemotherapy or radiation to kill any resident cancer cells, suppress the patient's immune system, and leave a disease-free environment into which healthy new blood stem cells can be infused. Known as myeloablation, the regimen prepares the patient to accept a "non-self" graft without triggering a severe attack on the patient by the transplant (graft vs. host disease).

Preparing Patients for Myeloablative Allogeneic Transplants

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov